Author: Christa Nath

Population pharmacokinetics of total and unbound melphalan in patients with multiple myeloma

CE Nath (1), PJ Shaw (1,7), J Trotman (2), L Zeng (1), S Duffull (8), AJ McLachlan (2,7), H Gurney (3,7), Y Kwan (2), P Presgrave (4), C Tiley (5), D Joshua (6,7), I Kerridge (3,7), J Earl (1)
(1) The Children

Background: Melphalan, an alkylating agent, is an active chemotherapeutic agent in the treatment of multiple myeloma. High dose melphalan is used prior to autografting, but additional knowledge about the pharmacokinetics, combined with toxicity and efficacy data is needed to optimise the dose. Aims: To (1) investigate the pharmacokinetics of total and unbound plasma melphalan using a population approach […]

Read More

Population pharmacokinetics of melphalan in myeloma patients undergoing an autograft

CE Nath (1), PJ Shaw(1,8), J Trotman (2), L Zeng (1), H Gurney (3), AJ McLachlan (2,8), I Kerridge (3), Y Kwan (2,6), P Presgrave (4), C Tiley (5), D Joshua (6), J Earl (1)
(1) The Children

Background: High dose melphalan is standard conditioning for autologous stem cell transplantation in the treatment of multiple myeloma. Appropriate dosing is critical as melphalan may be associated with profound toxicity, including cytopenia and gastrointestinal toxicity, which can lead to significant treatment-related mortality, while insufficient dose intensity can lead to disease relapse. The aim of this study was […]

Read More